Jan Pinkas
Hoofd Techniek/Wetenschap/O&O bij PYXIS ONCOLOGY, INC.
Actieve functies van Jan Pinkas
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| PYXIS ONCOLOGY, INC. | Hoofd Techniek/Wetenschap/O&O | 12-04-2022 | - |
| Corporate Officer/Principal | 01-08-2021 | 12-04-2022 |
Loopbaan van Jan Pinkas
Eerdere bekende functies van Jan Pinkas
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| IMMUNOGEN, INC. | Corporate Officer/Principal | - | - |
| MAGENTA THERAPEUTICS | Corporate Officer/Principal | - | - |
Opleiding van Jan Pinkas
| University of Massachusetts | Doctorate Degree |
| The Johns Hopkins University | Undergraduate Degree |
Statistieken
Internationaal
| Verenigde Staten | 6 |
Operationeel
| Corporate Officer/Principal | 3 |
| Chief Tech/Sci/R&D Officer | 1 |
| Doctorate Degree | 1 |
Sectoraal
| Health Technology | 4 |
| Consumer Services | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| PYXIS ONCOLOGY, INC. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Magenta Therapeutics, Inc.
 Magenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Magenta Therapeutics, Inc. is a biotechnology company, which focuses on improving stem cell transplantation. Its platform includes MGTA-117, MGTA-145, and CD45-ADC. The company was founded by David T. Scadden, Derrick J. Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner on June 17, 2015 and is headquartered in Cambridge, MA. | Health Technology |
ImmunoGen, Inc.
 ImmunoGen, Inc. BiotechnologyHealth Technology ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded on March 27, 1981 and is headquartered in Waltham, MA. | Health Technology |
- Beurs
- Insiders
- Jan Pinkas
- Ervaring
